Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2024 | Advancing multidisciplinary management of oligometastatic gastroesophageal cancer

Radka Obermannova, MD, PhD, Masaryk University, Brno, Czech Republic, highlights the significance of multidisciplinary care in a session at the European Society for Medical Oncology (ESMO) 2024 Congress, which brought together surgeons, radiation oncologists, medical oncologists, among others, to discuss the complexities of oligometastatic disease. While there is a European consensus on its definition, not all countries have accepted it. The session emphasized the need for more biomarker-oriented studies and next-generation trials to improve the understanding of the biology of oligometastatic disease and optimize treatment strategies. This interview took place at the ESMO 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.